Dr. Ilaria S Pagani joined the Leukaemia Research Group at SAHMRI in July 2014, developing two projects on chronic myeloid leukaemia (CML).
CML is a myeloproliferative disease characterize by the t(9;22)(q34;q11) balanced reciprocal translocation. The hallmark of the CML is the BCR/ABL1 fusion gene on Philadelphia chromosome (Ph), which encodes for a constitutively active protein tyrosine kinase (TK) that confers proliferative advantages to the Ph-positive clone. Tyrosine kinase inhibitors (TKIs) dramatically improved the survival of chronic myeloid leukaemia (CML) patients. TK inhibitors (TKIs) have revolutionized the management of the CML, providing target therapy for patients. Despite the success of TKIs in long-term survival, variations in treatment outcome suggest a possible secondary mechanism of resistance due to the persistence of a pre-existing clone that had acquired additional genetic lesions.
The first project is the characterization of the genomic landscape of mitochondrial (mt) DNA mutations in CML by next generation sequencing techniques, identifying a sub-group of patients that do not respond to the therapy. Next goal will be to determine whether mtDNA mutations influence the susceptibility of CML cells to undergo apoptosis in response to tyrosine kinase inhibition.
Approximatively half of patients who achieved a deep molecular response and maintain it for 1-2 years, experienced molecular relapse after stopping TKI-therapy. Dr. Pagani is investigating whether the lineage and proliferative potential of residual leukaemic cells are key determinant of treatment free remission after stopping therapy.
✓ Eligible to supervise Masters and PhD — email supervisor to discuss availability.
|2017 - 2020||Affiliated Lecturer||University of Adelaide, Adelaide|
|2015 - 2018||Post-Doctoral Researcher||South Australian Health and Medical Research Institute, Adelaide|
|2014 - 2014||Visiting-Post Doc||South Australian Health and Medical Research Institute, Adelaide|
|2012 - 2014||Post-Doctoral Researcher||University of Rome Tor Vergata, Rome|
|2012 - 2012||Visiting Post-Doc||Medical Research Council (MRC), London|
|2011 - 2012||Post-Doctoral Researcher||University of Insubria, Varese|
|2018||Award||Best poster Award||New Directions in Leukaemia Research (NDLR) 2018 Meeting||Australia||$250|
|2018||Invitation||Invited speaker to the Cancer in SA Translational Research Meeting, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia.||South Australian Health and Medical Research Institute (SAHMRI)||Australia|
|2018||Invitation||Technical expert/guide to the Italian Delegation in SAHMRI||South Australian Health and Medical Research Institute (SAHMRI)||Australia|
|2016||Invitation||Invited to judge oral/poster presentations for the EMBL Australia Postgraduate Symposium 2016 at SAHMRI, Adelaide, Australia.||EMBL Australia||Australia|
|2016||Achievement||Invited speaker to the 2016 Leukaemia Foundation Patient Education Conference, CML Session, Adelaide University, Australia.||Leukaemia Foundation||Australia|
|2016||Achievement||Invited speaker to the Hematology Seminar, S.A. Pathology, Adelaide, SA, Australia||SA Pathology||Australia|
|2016||Achievement||Invited speaker to the Cancer in SA Translational Research Meeting, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia.||South Australian Health and Medical Research Institute (SAHMRI)||Australia|
|2016||Award||Competitive selective Beat Cancer Project Travel Grant 2016||Cancer Council South Australia||Australia||$1250|
|2015||Achievement||Invited speaker to the Blood Club Translational Research Meeting, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia.||South Australian Health and Medical Research Institute (SAHMRI)||Australia|
|2014||Award||Top 10 Best Abstracts||European Society Human Genetics (ESHG), Milan, Italy||Italy|
|2013||Award||American Society of Hematology (ASH) International Post-doctoral Fellow (IPDF) approval and $500 ASH Abstract Achievement Award||American Society of Hematology (ASH)||Italy||$500|
|2012||Fellowship||competitive selective 3 years - Italian Association for Cancer Research" (AIRC) Fellowship||Italian Association for Cancer Research (AIRC)||Italy|
|2011||Award||Competitive Selective Travel Fellowship covering all expenses to participate at the 11th FEBS Young Scientist Forum and at 36th FEBS Congress.||FEBS||Italy|
|2011||Fellowship||Italian Association against Leukaemia and Lymphoma (AIL) Fellowship||Italian Association against Leukaemia and Lymphoma (AIL)||Italy|
|2007||Scholarship||Insubria University PhD Scholarship, Varese, Italy.||Insubria University||Italy|
|English||Can read, write, speak, understand spoken and peer review|
|French||Can read, write, speak and understand spoken|
|Italian||Can read, write, speak, understand spoken and peer review|
|2011 - 2016||University of Milan, Milan||Italy||Specialist in Medical Genetics|
|2011||University of Insubria, Varese||Italy||PhD|
|2007||University of Insubria, Varese||Italy||Master Degree in Molecular Biology|
|2008||State Examination for the qualification in Biologi||University of Insubria, Varese||Italy|
|2017||Pagani, I., Kok, C., Saunders, V., Van der Hoek, M., Heatley, S., Schwarer, A., . . . Ross, D. (2017). A Method for Next-Generation Sequencing of Paired Diagnostic and Remission Samples to Detect Mitochondrial DNA Mutations Associated with Leukemia. The Journal of molecular diagnostics : JMD, 19(5), 711-721.
|2015||Porta, G., Pagani, I. S., & Pirrone, C. (2015). gDNA Q-PCR for clinical monitoring of CML. Cell Cycle, 14(23), 3659-3660.
|2014||Pagani, I. S., Spinelli, O., Mattarucchi, E., Pirrone, C., Pigni, D., Amelotti, E., . . . Porta, G. (2014). Genomic quantitative real-time PCR proves residual disease posivitity in more than 30% samples with negative mRNA-based qRT-PCR in Chronic Myeloid Leukemia. Oncoscience.|
|2013||Azzolini, C., Pagani, I. S., Pirrone, C., Borroni, D., Donati, S., Al Oum, M., . . . Porta, G. (2013). Expression of VEGF-A, Otx Homeobox and p53 Family Genes in Proliferative Vitreoretinoipathy.. Mediators of Inflammation.|
|2011||Terrinoni, A., Pagani, I., Zucchi, I., Chiaravalli, A., Serra, V., Rovera, F., . . . Porta, G. (2011). OTX1 expression in breast cancer is regulated by p53. Oncogene, 30(27), 3104.
|2010||Pagani, I. S., Terrinoni, A., Marenghi, L., Zucchi, I., Chiaravalli, A. M., Serra, V., . . . Porta, G. (2010). The Mammary Gland and the Homeobox Gene Otx1. The Breast Journal, 16, S53-S56.
|2017||Ross, D. M., Pagani, I. S., Shanmuganathan, N., Seymour, J. F., Mills, A. K., Filshie, R. J., . . . Hughes, T. P. (2017). Long-term Follow-up of the ALLG CML8 TWISTER Study of Treatment-free Remission (TFR) in Patients With Chronic Myeloid Leukemia (CML).. In Blood. Atlanta: American Society of Hematology.|
|2017||Pagani, I. S., Dang, P., Kommers, I. O., Goyne, J., Saunders, V. A., Prime, J. A., . . . Ross, D. M. (2017). Comparison of genomic and reverse transcriptase Q-PCR for the monitoring of first-line imatinib treatment: an ALLG CML9 sub-study. In Haematologica. Madrid: Ferrata Storti Foundation.|
|2016||Pagani, I. S., Kok, C. H., Saunders, V., Goyne, J., McLean, J., VanderHoek, M., . . . Ross, D. M. (2016). The genomic landscape of mitochondrial DNA mutations in chronic myeloid leukaemia.. In European Journal of Human Genetics. Barcelona: Natue Publishing Group.|
|2016||Pagani, I., Kok, C. H., Wang, J., Saunders, V., Goyne, J., McLean, J., . . . Ross, D. (2016). MITOCHONDRIAL DNA MUTATIONS IDENTIFY CLONAL HETEROGENEITY IN CHRONIC MYELOID LEUKAEMIA. In HAEMATOLOGICA Vol. 101 (pp. 234). Copenhagen, DENMARK: FERRATA STORTI FOUNDATION.|
|2014||Pagani, I. S., Pirrone, C., & Amelotti, E. (2014). TAp73α regulates Otx1 expression during breast cancer stem cells differentiation and in response to cisplatin treatment.. In European Journal of Human Genetics. Milan: Nature Publishing Group.|
|2014||Pirrone, C., & Pagani, I. S. (2014). New molecular technique to monitor minimal residual diseased in CML. In European Journal of Human Genetics. Milan: Nature Publishing Group.|
|2014||Pagani, I. S. (2014). Genomic quantitative real-time PCR assay proves residual disease positivity in more than 30% samples with negative mRNA-based qRT-PCR results in Chronic Myeloid Leukemia.. In Bone Marrow Transplantation. Milan: Nature Publishing Group.|
|2013||Pagani, I. S. (2013). Quantitative DNA Real-Time PCR Compared To mRNA and Cytogenetic Assays To Monitor Minimal Residual Disease In Chronic Myeloid Leukemia. In Blood. New Orleans: American Society of Hematology.|
|2013||Azzolini, C., & Pagani, I. S. (2013). Expression Of VEGF-A Gene In Normal Retina And In PVR Retina. In Investigative Ophthalmology & Visual Science. Seattle: Association for Research in Vision and Ophthalmology.|
|2012||Azzolini, C., & Pagani, I. S. (2012). Otx2 And VegfA Expression And P53-Otx1 Differentiation Pathway In Proliferative Vitreoretinopathy. In Investigative Ophthalmology & Visual Science. Fort Lauderdale, Florida, US: Association for Research in Vision and Ophthalmology.|
|2011||Pagani, I. S. (2011). Chronic myeloid leukemia: molecular monitoring of residual disease by genomic DNA compared to conventional mRNA analysis in follow-ups up to 8 year. In Blood. Sand Diego, US: American Society of Hematology.|
|2011||Pagani, I. S. (2011). p53 family members regulate the Otx1 gene expression in differentiation of breast cancer stem cells and in mammary gland development. In FEBS Journal. Torino, Italy: Blackwell Publishing Inc..|
|2011||Azzolini, C., Donati, C., Borroni, D., Moriondo, A., & Pagani, I. S. (2011). Evaluation of the p53-Otx1 pathway in the retina.. In Investigative Ophthalmology & Visual Science. Fort Lauderdale, Florida, US: Association for Research in Vision and Ophthalmology.|
- 2016: Biochemistry III tutorial, Adelaide University, Australia.
- 2007-2013: Tutorial of Laboratory Techniques and genetics to Medicine Students, Insubria University, Varese, Italy.
|Date||Role||Research Topic||Location||Program||Supervision Type||Student Load||Student Name|
|2018 - ongoing||Principal Supervisor||Mitochondrial DNA mutations in CML||The University of Adelaide||Placement||Other||Part Time||Samuel Cannata, Rico Acuna|
|2018 - ongoing||Co-Supervisor||Mitochondrial DNA copy Numbers in MPN||UniSA||Placement||Other||Part Time||Lian Thuy|
|2017 - ongoing||Principal Supervisor||Monitoring BCR-ABL content in 2 Chronic Myeloid Leukaemia (CML) Patients Involved in a Trial of Treatment Free Remission (TFR)||The University of Adelaide||Placement||Other||Part Time||Caitlin Skinner|
|2014 - ongoing||Co-Supervisor||Next generation Sequencing in CML||Insubria University||Postdoctorate||Pirrone Cristina|
|2011 - ongoing||Principal Supervisor||Monitoring of minimal residual disease in CML by gDNA QPCR||Insubria University, Varese, Italy||Master||Full Time||Giorgia Aimoni|
|2011 - ongoing||Principal Supervisor||Monitoring of Minimal Residual Disease in CMl||Insubria University||Master||Pirrone Cristina|
|2011 - 2013||Principal Supervisor||Next-Generation Sequencing as a new approach to monitor minimal residual disease in CML||Insubria University||Doctorate||Full Time||Pirrone Cristina|
|2011 - ongoing||Co-Supervisor||p53-Otx1 in retina||Faculty of Medicine, Insubria University,||Master||Borroni Davide|
|2009 - 2011||Principal Supervisor||p53 and Otx1 in Glioblastoma and Breast Cancer||Faculty of Medicine, Insubria University||Placement||Other||Annalisa Paolino, Eleonora Scotti, Martina Baiardo|